This Article Full Text Full Text (PDF) All Versions of this Article: 38/9/e91    most recent STROKEAHA.107.487884v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Alegre, E. J. Articles by Ríos, E. Search for Related Content PubMed PubMed Citation Articles by Alegre, E. J. Articles by Ríos, E.

(Stroke. 2007;38:e91.)
© 2007 American Heart Association, Inc.

Letters to the Editor

Alteplase for Patients With Ictus: the Dilemma Persists

Pharmacy Department, Puerto Real Universitary Hospital, Cádiz, Spain

An extract of the first 250 words of the full text is provided, because this article has no abstract.

To the Editor:

Therapeutic usefulness of alteplase in patients with ischemic stroke is a complex topic. Perhaps some clinical trials with good methodology exist; they are very different in patients, treatment and results.

From a wide point of view, as of the Wardlaw et al metaanalysis,¹ alteplase administration could increase all-cause mortality in 1.9% (95% CI, –0.6% to 4.8%). In spite of this, it favors recovery from stroke, so 5.5% more patients become dependence-free (number needed to treat=18; P<0,05). Although that possible rise in mortality (consequence of cerebral heamorrhage as a thrombolysis effect) does not reach statistical significance in the metaanalysis, a statistically significant increase of fatal cerebral hemorrhage in 2.5% of patients (P<0.05) has been shown.

This presents a dilemma because we could improve likelihood of recovery, but along with a life-threatening hazard. Probably thereby, alteplase treatment is not so widely spread as some authors expected (<5% of ischemic stroke patients receive it in the United States).² Besides, as heterogeneity of results is high among studies, it is usually accepted to follow inclusion criteria of the study that show a wider pool of evidence favorable to alteplase use.³ That study (NINDS)⁴ is the pivotal clinical trial for this indication approval at FDA, a very strict study with 0.9 mg/Kg (maximum 90 mg) dose of alteplase, in patients with no more to 180 minutes from arise of symptoms (with a standardized time stimation), exclusion for age, historial and diagnostic matters, including CT to exclude hemorrhagic stroke, as . . . [Full Text of this Article]